Login to Your Account



Nabi Digs Deep, Finds Reason To Continue StaphVAX Work

By Karen Pihl-Carey


Thursday, March 23, 2006
News that Nabi Biopharmaceuticals intends to continue development of its Gram-positive programs - which includes the lead drugs StaphVAX and Altastaph - restored investor hopes Wednesday, as the company’s stock climbed 15.8 percent. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription